Clinical trial · Observational
An International Study on Pediatric Patients With Rare Tumors.
The PARTNER Study - An International Prospective Observational Study on Pediatric Patients With Very Rare Tumors.
NCT07072143CI-TRIAL-00092332PARTNERrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.
Conditions
Conditions (14)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adrenocortical Tumor | Adrenal Cortical Neoplasm | ALIAS | 0.90 |
| Appendiceal Cancers | Malignant Appendix Neoplasm | ALIAS | 0.90 |
| Esthesioneuroblastoma, Olfactory | Olfactory Neuroblastoma | ALIAS | 0.90 |
| Gastrointestinal Stromal Tumor (GIST) | Gastrointestinal Stromal Tumor | CURATED_BROADER | 0.80 |
| Melanoma and Other Malignant Neoplasms of Skin | — | UNRESOLVED | — |
| Mesothelioma | Malignant Mesothelioma | CURATED_EXACT | 0.92 |
| Nasopharyngeal Carcinoma (NPC) | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.85 |
| NUT Carcinoma | NUT Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Pancreatic Tumors | Pancreatic Neoplasm | ALIAS |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Epidemiology
- timeFrame
- through study completion, an average of 1 year
- description
- Evaluate the number of patients (aged 0-18 years) with different Very Rare Tumors in the different countries: observed cases will be compared with expected cases.
- measure
- Use of International Recommendations
- timeFrame
- through study completion, an average of 1 year
- description
- The study aims to measure the number of patients treated for different neoplasms in different countries, and the proportion of those treated in accordance with the International Recommendations.
- measure
- Survival of children and adolescents (0-18 years) affected by Very Rare Tumors
- timeFrame
- through study completion, an average of 1 year
- description
- The study will correlate the clinical characteristics of the tumor (size, site, extension) with the treatment, the risk of recurrence and survival.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 0 Years
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Children and adolescents (age 0-18 years) with a primary or relapsed Very Rare Tumor diagnosed and/or treated in a participating country/center. * Written informed consent from the patient and/or the parent/legal guardian Exclusion Criteria: * Absence of Written informed consent from the patient and/or the parent/legal guardian
References
Publications (1)
- BACKGROUNDOrbach D, Ferrari A, Schneider DT, Reguerre Y, Godzinski J, Bien E, Stachowicz-Stencel T, Surun A, Almaraz RL, Dragomir M, Jani D, Ami TB, Roganovic J, Brecht IB, Ladenstein R, Bisogno G. The European Paediatric Rare Tumours Network - European Registry (PARTNER) project for very rare tumors in children. Pediatr Blood Cancer. 2021 Jun;68 Suppl 4:e29072. doi: 10.1002/pbc.29072. Epub 2021 Apr 29. PMID 33913610